AtaiBeckley Inc. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
3.700
-0.060 (-1.60%)
At close: Apr 9, 2026, 4:00 PM EDT
3.710
+0.010 (0.27%)
After-hours: Apr 9, 2026, 7:59 PM EDT
AtaiBeckley Employees
AtaiBeckley had 99 employees as of December 31, 2025. The number of employees increased by 45 or 83.33% compared to the previous year.
Employees
99
Change (1Y)
45
Growth (1Y)
83.33%
Revenue / Employee
$41,303
Profits / Employee
-$6,667,141
Market Cap
1.35B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 99 | 45 | 83.33% |
| Dec 31, 2024 | 54 | -29 | -34.94% |
| Dec 31, 2023 | 83 | -50 | -37.59% |
| Dec 31, 2022 | 133 | 46 | 52.87% |
| Dec 31, 2021 | 87 | 52 | 148.57% |
| Mar 31, 2021 | 35 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Novavax | 749 |
| Immatics | 711 |
| Wave Life Sciences | 317 |
| Biohaven | 274 |
| Monte Rosa Therapeutics | 150 |
| Maze Therapeutics | 141 |
| Olema Pharmaceuticals | 131 |
ATAI News
- 1 day ago - AtaiBeckley Depression Drug Delivers Rapid Day-2 Antidepressant Response - Benzinga
- 1 day ago - AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - GlobeNewsWire
- 16 days ago - AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst - GlobeNewsWire
- 4 weeks ago - BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - GlobeNewsWire
- 4 weeks ago - AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update - GlobeNewsWire
- 6 weeks ago - AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data - Benzinga
- 6 weeks ago - AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder - GlobeNewsWire
- 6 weeks ago - AtaiBeckley To Host Virtual Investor Day on March 6, 2026 - GlobeNewsWire